Table 2.

Baseline characteristics of patients before and after propensity score matching

Characteristics	Before matching			p value	After matching			p value
	overall (n = 174)	central arm (n = 64)	peripheral arm (n = 110)		overall (n = 96)	central arm (n = 48)	peripheral arm (n = 48)
Age (mean±SD), years	71.2±9.8	70.2±11.5	71.8±8.5	0.688	70.3±9.5	71.2±10.6	69.4±8.1	0.231
Sex (male/female)	120/54	48/16	72/38	0.189	69/27	35/13	34/14	0.820
Etiology (viral/nonviral)	129/45	43/21	86/24	0.110	73/23	34/14	39/9	0.232
Child-Pugh score (mean±SD)	5.85±1.13	5.77±1.07	5.90±1.17	0.515	5.94±1.20	5.83±1.10	6.04±1.30	0.529
Child-Pugh (A/B)	130/44	49/15	81/29	0.669	71/25	36/12	35/13	0.816
ALBI score (mean±SD)	−2.37±0.52	−2.38±0.49	−2.36±0.54	0.870	−2.30±0.53	−2.35±0.48	−2.25±0.57	0.505
ALBI grade (1/2a/2b/3)	64/37/65/8	23/15/24/2	41/22/41/6	0.868	32/20/37/7	16/12/18/2	16/8/19/5	0.549
BCLC (0/A/B)	9/92/73	1/30/33	8/62/40	0.065	4/54/38	1/26/21	3/28/17	0.474
Largest tumor diameter (mean±SD), cm	3.5±2.2	4.5±3.0	3.0±1.3	<0.001*	3.4±1.5	3.4±1.5	3.3±1.5	0.538
Largest tumor diameter (n) (≤5 cm/>5 cm)	151/23	49/15	102/8	0.002*	85/11	44/4	41/7	0.336
Tumor number/patient (median, range)	2 (1–150)	2 (1–82)	2 (1–150)	0.132	2 (1–100)	2 (1–82)	1(1–100)	0.199
Tumor number (n) (<4/≥4)	123/51	40/24	83/27	0.070	70/26	31/17	39/9	0.066
Up-to-7 criteria (n) (in/out)	121/53	37/27	84/26	0.010*	70/26	33/15	37/11	0.358
AFP, ng/mL (median, range)	13.8 (2–1,039,586)	19.6 (2–1,039,586)	12.7 (2–5,732.5)	0.360	13.5(2–5,732.5)	11.5(2–3,479.1)	14.1(2–5,732.5)	0.287
AFP (n) (<400 ng/mL/≥400 ng/mL)	147/27	51/13	96/14	0.183	83/13	42/6	41/7	0.766
PIVKA-II, mAU/mL (median, range)	153 (9–238,237)	236 (10–238,237)	120 (9–27,289)	0.010*	142(10–34,603)	144(10–34,603)	133(12–19,441)	0.421
PIVKA-II (n) (<300 mAU/mL/≥300 mAU/mL)	108/66	35/29	73/37	0.126	62/34	32/16	30/18	0.670

ALBI, albumin-bilirubin; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonists-II.

*p value <0.05.